NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

Conditions: Anaplastic Thyroid Cancer Interventions: Drug: dabrafenib/trametinib Sponsors: Leiden University Medical Center; Novartis Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials